NEW YORK – Microbix Biosystems and Seegene USA on Thursday said they have signed an agreement for Seegene to distribute and recommend Microbix's Quality Assessment Products (QAPs) to monitor the workflow accuracy of Seegene's Novaplex and Allplex assays.
Seegene USA will distribute the QAPs along with its Allplex and Novaplex PCR assays for infectious diseases. The QAPs are available for use with PCR assays and Copan FLOQSwabs at room temperature or refrigerator-stable liquid vials.
Financial and other terms of the deal were not disclosed. Microbix and Seegene Canada also signed in 2021 a distribution agreement for Microbix's COVID-variant QAPs with Seegene's Allplex assays in Canada.
Irvine, California-based Seegene USA is a subsidiary of South Korea-based Seegene. The company's RT-PCR Novaplex syndromic assay reagents are for research use only, while its Allplex 2019-nCoV assay is available in the US under Emergency Use Authorization from the US Food and Drug Administration. Microbix's ProceeDx QAPs are available for research use only, and its ReDx QAPs are in vitro diagnostic controls.
"Our collaboration naturally aligns the two companies to help assure optimal results for laboratories performing high-multiplex PCR testing using Seegene assays," Microbix Senior VP of Business Development Philip Casselli said in a statement.
Craig Howell, senior VP for marketing at Seegene USA, added that the partnership increases the firm's in vitro diagnostics presence in the US and helps lab customers improve the quality of their results.